Doxazosin

Doxazosin
Clinical data
Pronunciation/dɒkˈseɪzəsɪn/
dok-SAY-zə-sin OR
/ˌdɒksəˈzoʊsɪn/
DOK-sə-ZOH-sin
Trade namesCardura, Carduran, others
AHFS/Drugs.comMonograph
MedlinePlusa693045
License data
Routes of
administration		By mouth
Drug classα1 blocker
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability65%
Protein binding98%
MetabolismLiver
Elimination half-life22 hours
Identifiers
  • (RS)-2-[4-(2,3-Dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.128.642 Edit this at Wikidata
Chemical and physical data
FormulaC23H25N5O5
Molar mass451.483 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)C4Oc5c(OC4)cccc5
  • InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26) checkY
  • Key:RUZYUOTYCVRMRZ-UHFFFAOYSA-N checkY
  (verify)

Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD).[1][2] For high blood pressure, it is a less preferred option.[2] It is taken by mouth.[2]

Common side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain.[2] Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism.[2][3] It is a selective α1-adrenergic blocker in the quinazoline class of compounds.[2]

Doxazosin was patented in 1977 and came into medical use in 1988.[4] It is available as a generic medication.[3] In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6]

  1. ^ a b "Cardura- doxazosin mesylate tablet". DailyMed. Retrieved 18 June 2021.
  2. ^ a b c d e f "Doxazosin Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
  3. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 765. ISBN 9780857113382.
  4. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.
  5. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  6. ^ "Doxazosin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.